{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:10:29Z","timestamp":1766387429014,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,21]]},"DOI":"10.7759\/cureus.99805","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:08:18Z","timestamp":1766387298000},"source":"Crossref","is-referenced-by-count":0,"title":["Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists"],"prefix":"10.7759","author":[{"given":"Andr\u00e9","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"MacAulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul R","family":"Khater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Mohrir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Joint Registry. Annual report 2024. (2024). Accessed: 2025: https:\/\/www.njrcentre.org.uk\/national-joint-registry-annual-report-2024\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.07.003","article-title":"Impact of obesity on the risk of wound infection following surgery: results from a nationwide prospective multicentre cohort study in England","volume":"21","author":"Thelwall S","year":"2015","unstructured":"Thelwall S, Harrington P, Sheridan E, Lamagni T. Impact of obesity on the risk of wound infection following surgery: results from a nationwide prospective multicentre cohort study in England. Clin Microbiol Infect. 2015, 21:1008.e1-8. 10.1016\/j.cmi.2015.07.003","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.23.01413","article-title":"Outcomes of obese patients undergoing primary total knee arthroplasty: trends over 30 years","volume":"106","author":"Uvodich ME","year":"2024","unstructured":"Uvodich ME, Dugdale EM, Pagnano MW, Berry DJ, Abdel MP, Bedard NA. Outcomes of obese patients undergoing primary total knee arthroplasty: trends over 30 years. J Bone Joint Surg Am. 2024, 106:1963-70. 10.2106\/JBJS.23.01413","journal-title":"J Bone Joint Surg Am"},{"key":"ref4","unstructured":"Health Survey for England. (2024). Accessed. 2025: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.05.025","article-title":"The current economic challenges in total joint arthroplasty","volume":"40","author":"Scuderi GR","year":"2025","unstructured":"Scuderi GR, Mont MA. The current economic challenges in total joint arthroplasty. J Arthroplasty. 2025, 40:1658-9. 10.1016\/j.arth.2025.05.025","journal-title":"J Arthroplasty"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70183-9","article-title":"Bone loss after bariatric surgery: causes, consequences, and management","volume":"2","author":"Stein EM","year":"2014","unstructured":"Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and management. Lancet Diabetes Endocrinol. 2014, 2:165-74. 10.1016\/S2213-8587(13)70183-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2014.02.021","article-title":"Bariatric surgery prior to total joint arthroplasty may not provide dramatic improvements in post-arthroplasty surgical outcomes","volume":"29","author":"Inacio MC","year":"2014","unstructured":"Inacio MC, Paxton EW, Fisher D, Li RA, Barber TC, Singh JA. Bariatric surgery prior to total joint arthroplasty may not provide dramatic improvements in post-arthroplasty surgical outcomes. J Arthroplasty. 2014, 29:1359-64. 10.1016\/j.arth.2014.02.021","journal-title":"J Arthroplasty"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0406","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - executive summary","volume":"25","author":"Mechanick JI","year":"2019","unstructured":"Mechanick JI, Apovian C, Brethauer S, et al.. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - executive summary. Endocr Pract. 2019, 25:1346-59. 10.4158\/GL-2019-0406","journal-title":"Endocr Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref11","article-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. London","year":"2024","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.. Higgins JP, Thomas J (ed). Cochrane, London, UK; 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref15","unstructured":"Review Manager Web (RevMan Web). Version 5.4. (2020). Accessed. 2025: https:\/\/revman.cochrane.org\/myReviews."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Does semaglutide use decrease complications and costs following total knee arthroplasty?","volume":"38","author":"Magruder ML","year":"2023","unstructured":"Magruder ML, Yao VJ, Rodriguez AN, Ng MK, Sasson V, Erez O. Does semaglutide use decrease complications and costs following total knee arthroplasty?. J Arthroplasty. 2023, 38:2311-15.e1. 10.1016\/j.arth.2023.05.071","journal-title":"J Arthroplasty"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions","volume":"39","author":"Magruder ML","year":"2024","unstructured":"Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA. Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. J Arthroplasty. 2024, 39:716-20. 10.1016\/j.arth.2023.12.023","journal-title":"J Arthroplasty"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty","volume":"39","author":"Buddhiraju A","year":"2024","unstructured":"Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024, 39:2911-5.e1. 10.1016\/j.arth.2024.05.079","journal-title":"J Arthroplasty"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.12.008","article-title":"Utilization of glucagon-like peptide-1 receptor agonists at the time of total hip arthroplasty for patients with morbid obesity","volume":"40","author":"Kim BI","year":"2025","unstructured":"Kim BI, Khilnani TK, LaValva SM, Goodman SM, Della Valle AG, Lee GC. Utilization of glucagon-like peptide-1 receptor agonists at the time of total hip arthroplasty for patients with morbid obesity. J Arthroplasty. 2025, 40:S259-64.e1. 10.1016\/j.arth.2024.12.008","journal-title":"J Arthroplasty"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.24.00468","article-title":"Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA","volume":"107","author":"Kim BI","year":"2025","unstructured":"Kim BI, LaValva SM, Parks ML, Sculco PK, Della Valle AG, Lee GC. Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA. J Bone Joint Surg Am. 2025, 107:348-55. 10.2106\/JBJS.24.00468","journal-title":"J Bone Joint Surg Am"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2024.101506","article-title":"Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total knee arthroplasty in patients with type-2 diabetes","volume":"30","author":"Heo KY","year":"2024","unstructured":"Heo KY, Goel RK, Fuqua A, et al.. Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total knee arthroplasty in patients with type-2 diabetes. Arthroplast Today. 2024, 30:101506. 10.1016\/j.artd.2024.101506","journal-title":"Arthroplast Today"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-24-01284","article-title":"The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty","volume":"33","author":"Levidy MF","year":"2025","unstructured":"Levidy MF, Vatsia S, Gohel N, Rowe N, Kirchner GJ, Demedal S, Mason M. The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty. J Am Acad Orthop Surg. 2025, 33:1213-8. 10.5435\/JAAOS-D-24-01284","journal-title":"J Am Acad Orthop Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.03.012","article-title":"GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?","volume":"40","author":"Verhey JT","year":"2025","unstructured":"Verhey JT, Austin RP, Tarabichi S, et al.. GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?. J Arthroplasty. 2025, 40:S101-7. 10.1016\/j.arth.2025.03.012","journal-title":"J Arthroplasty"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes: systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes: systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039446","article-title":"Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a\u00a0systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Liu Y","year":"2025","unstructured":"Liu Y, He L, Han S, et al.. Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a\u00a0systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2025, 14:e039446. 10.1161\/JAHA.124.039446","journal-title":"J Am Heart Assoc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.61200","article-title":"Postoperative weight loss after anti-obesity medications and revision risk after joint replacement","volume":"8","author":"Xie D","year":"2025","unstructured":"Xie D, Englund M, Lane NE, et al.. Postoperative weight loss after anti-obesity medications and revision risk after joint replacement. JAMA Netw Open. 2025, 8:e2461200. 10.1001\/jamanetworkopen.2024.61200","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440466-reducing-periprosthetic-joint-infection-in-patients-with-obesity-a-systematic-review-and-meta-analysis-of-the-emerging-role-of-glucagon-like-peptide-1-glp-1-receptor-agonists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:08:20Z","timestamp":1766387300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440466-reducing-periprosthetic-joint-infection-in-patients-with-obesity-a-systematic-review-and-meta-analysis-of-the-emerging-role-of-glucagon-like-peptide-1-glp-1-receptor-agonists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.99805","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}